BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Molnár E, Garay T, Donia M, Baranyi M, Rittler D, Berger W, Tímár J, Grusch M, Hegedűs B. Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR Expression. Int J Mol Sci 2019;20:E4484. [PMID: 31514305 DOI: 10.3390/ijms20184484] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Wessely A, Steeb T, Berking C, Heppt MV. How Neural Crest Transcription Factors Contribute to Melanoma Heterogeneity, Cellular Plasticity, and Treatment Resistance. Int J Mol Sci 2021;22:5761. [PMID: 34071193 DOI: 10.3390/ijms22115761] [Reference Citation Analysis]
2 Dent P, Booth L, Poklepovic A, Kirkwood JM. Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling. Pigment Cell Melanoma Res 2021. [PMID: 34482636 DOI: 10.1111/pcmr.13014] [Reference Citation Analysis]
3 Proietti I, Skroza N, Bernardini N, Tolino E, Balduzzi V, Marchesiello A, Michelini S, Volpe S, Mambrin A, Mangino G, Romeo G, Maddalena P, Rees C, Potenza C. Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review. Cancers (Basel) 2020;12:E2801. [PMID: 33003483 DOI: 10.3390/cancers12102801] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
4 Patel V, Szász I, Koroknai V, Kiss T, Balázs M. Molecular Alterations Associated with Acquired Drug Resistance during Combined Treatment with Encorafenib and Binimetinib in Melanoma Cell Lines. Cancers (Basel) 2021;13:6058. [PMID: 34885166 DOI: 10.3390/cancers13236058] [Reference Citation Analysis]
5 Booth L, West C, Von Hoff D, Kirkwood JM, Dent P. GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma Cells. Front Oncol 2021;11:656453. [PMID: 33898322 DOI: 10.3389/fonc.2021.656453] [Reference Citation Analysis]
6 Koroknai V, Patel V, Szász I, Ádány R, Balazs M. Gene Expression Signature of BRAF Inhibitor Resistant Melanoma Spheroids. Pathol Oncol Res 2020;26:2557-66. [PMID: 32613561 DOI: 10.1007/s12253-020-00837-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Li T, Zhang HB, Meng JM, Yuan B, Lin WJ, Feng Y, Chen XD. YM155 inhibits retinal pigment epithelium cell survival through EGFR/MAPK signaling pathway. Int J Ophthalmol 2021;14:489-96. [PMID: 33875937 DOI: 10.18240/ijo.2021.04.02] [Reference Citation Analysis]
8 Huang XF, Gao HW, Lee SC, Chang KF, Tang LT, Tsai NM. Juniperus indica Bertol. extract synergized with cisplatin against melanoma cells via the suppression of AKT/mTOR and MAPK signaling and induction of cell apoptosis. Int J Med Sci 2021;18:157-68. [PMID: 33390784 DOI: 10.7150/ijms.49423] [Reference Citation Analysis]
9 Olbryt M. Potential Biomarkers of Skin Melanoma Resistance to Targeted Therapy—Present State and Perspectives. Cancers 2022;14:2315. [DOI: 10.3390/cancers14092315] [Reference Citation Analysis]
10 Jandova J, Wondrak GT. Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor‒Resistant BRAFV600E/NRASQ61K Melanoma Enhancing Tumor Growth and Metastasis in a Bioluminescent Murine Model. J Invest Dermatol 2021:S0022-202X(21)02368-X. [PMID: 34687745 DOI: 10.1016/j.jid.2021.10.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Dratkiewicz E, Simiczyjew A, Pietraszek-Gremplewicz K, Mazurkiewicz J, Nowak D. Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment. Int J Mol Sci 2019;21:E113. [PMID: 31877948 DOI: 10.3390/ijms21010113] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
12 Frazao A, Rethacker L, Jeudy G, Colombo M, Pasmant E, Avril MF, Toubert A, Moins-Teisserenc H, Roelens M, Dalac S, Maubec E, Caignard A. BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis. J Immunother Cancer 2020;8:e000275. [PMID: 32912923 DOI: 10.1136/jitc-2019-000275] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]